NICE issues updated final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial rapid review of TA878)
Final draft guidance for nirmatrelvir plus ritonavir has been published by the National Institute for Health and Care Excellence (NICE), following a partial review of Multiple Technology Appraisal (MTA) TA878.
The Scottish Medicines Consortium (SMC) has had direct input into the decision-making committee that produced the final draft guidance.
The final draft guidance recommends nirmatrelvir plus ritonavir as an option for treating COVID-19 in adults for some additional risk groups, namely:
- age 70 years and over
- body mass index (BMI) of 35 kg/m2 or more
- diabetes
- heart failure
The date that Final Guidance is expected to be published is to be confirmed. Any amendments to the SMC collaborative advice document will occur following publication of the NICE final guidance.
The updated final draft guidance now includes a Funding Variation for application in NHS England. Further information on the implications of this for Scotland will follow from Scottish Government around the time that Final Guidance is published.
You can read more about the updated final draft guidance recommendations including the funding variation here: Final draft guidance: 2 | Project documents | Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878) [ID6262] | Guidance | NICE